1 A multicenter,
open-label,
24-week trial (VBP15-003) with a 24-month lo
2 iously reported immunogenicity data from the
open-label 28-d interval prime-boost group (SD/SD D28; n
3 Valve Implantation) trial is a multicenter,
open-label,
2x2 factorial, randomized trial of 447 patie
4 In AUGUSTUS (
Open-Label,
2x2 Factorial, Randomized, Controlled Clinic
5 CASSIOPEIA is an ongoing randomised,
open-label,
active-controlled, parallel-group, phase 3 t
6 ALCYONE was a multicentre, randomised,
open-label,
active-controlled, phase 3 trial that enroll
7 The phase 2a, proof-of-concept study was an
open-label,
adaptive dose-ranging design.
8 For this phase 2, single centre,
open-label,
adaptive, safety and efficacy randomised cli
9 I-SPY 2 is a multicenter, phase II,
open-label,
adaptively randomized neoadjuvant platform t
10 SIGN, SETTING, AND PARTICIPANTS: Randomized,
open-label,
adjudicator-blinded, phase 2 noninferiority
11 The trial was
open label,
and neither the investigators who took measu
12 ociated with and predictive of relapse after
open-label antidepressant discontinuation.
13 The success rate of
open-label antidepressant lead-ins without placebo or us
14 nsuming, expensive and, in some cases (i.e.,
open-label antidepressant without placebo or with double
15 domized to blinded aspirin or placebo and to
open-label apixaban or VKA for 6 months.
16 SIGN, SETTING, AND PARTICIPANTS: Randomized,
open-label,
blinded end-point clinical trial including 1
17 We did a prospective, randomised,
open-label,
blinded-endpoint, non-inferiority trial of f
18 s reduction of depressive symptoms following
open-label celecoxib administration in treatment-resista
19 In an
open label clinical trials, participants with ASD were a
20 We conducted a phase 1,
open-label clinical trial (no.
21 Term Effectiveness)-a pragmatic, randomized,
open-label clinical trial testing the optimal dose of as
22 patients with severe, long-standing GA in an
open-label clinical trial.
23 , AND PARTICIPANTS: Multicenter, randomized,
open-label,
clinical trial conducted in 41 intensive car
24 In this
open-label cluster-randomised controlled trial, we recru
25 We conducted an
open-label,
cluster-randomized trial involving asymptoma
26 reat HIV-1 infection, was administered as an
open label compassionate use therapeutic for COVID-19.
27 This
open-label,
consecutive-panel, phase 1b trial was done a
28 rtension, we conducted a 6-week, randomized,
open-label crossover trial comparing amiloride/hydrochlo
29 This was a randomized,
open-label,
crossover clinical trial in a tertiary hospi
30 roup were permitted to cross over to receive
open-label darolutamide treatment.
31 ther small proportion of women included, the
open label design, and its short duration.
32 Key limitations to the study were the
open-label design, and use of external comparators.
33 All participants took
open-label dipyridamole during weeks 12-24.
34 inary efficacy of mavorixafor from a phase 2
open-label dose-escalation and extension study in 8 adul
35 This phase I, nonrandomized,
open-label,
dose-escalation (DE), and extension-cohort (
36 This phase 1,
open-label,
dose-escalation and -expansion study (NCT020
37 InnovaTV 201 is a phase 1-2,
open-label,
dose-escalation and dose-expansion study don
38 NAVIGATOR is a two-part,
open-label,
dose-escalation and dose-expansion, phase 1
39 adoptive transfer in humans, we conducted an
open-label,
dose-escalation, Phase I clinical trial in l
40 We conducted a multicenter, randomized,
open-label,
dose-ranging controlled trial of telmisartan
41 Effects of
open-label drop-in cardioprotective medications need to
42 domized treatment for drug classes where >5%
open-label drop-in glucose-lowering medication occurred,
43 During median 3.2 years follow-up,
open-label drop-in occurred in 33.4% of participants, mo
44 Here,
open-label efficacy and safety experience of vamorolone
45 on (CAN-BIND-1) protocol received 8 weeks of
open-label escitalopram.
46 This multicentre,
open-label extension (OLE) trial enrolled patients at 43
47 for 12 weeks (part A), followed by a 40-week
open-label extension (part B), during which time all par
48 This study is a prespecified
open-label extension analysis of a phase 1 trial (NCT004
49 res of disease progression and safety in the
open-label extension phase of ORATORIO.
50 ble-blind, active-controlled studies (now in
open-label extension phase).
51 od to week 144; 527 (97%) of 544 entered the
open-label extension phase, of whom 451 (86%) are ongoin
52 uble-blind treatment period, 111 entered the
open-label extension study (74 from the PRM-151 group an
53 e ongoing (5-year treatment) PEOPLE (PEPITES
Open-Label Extension) study.
54 his period, patients could enter an optional
open-label extension, during which they continued ocreli
55 27, 2016, when the last patient entered the
open-label extension.
56 phase, of whom 451 (86%) are ongoing in the
open-label extension.
57 Given the reported promising results of
open-label fecal microbiota transplantation (FMT) therap
58 In this
open-label,
first-in-human trial, we have assessed the s
59 heir failing regimen for 8 days, followed by
open-label fostemsavir plus optimized background therapy
60 ining antiretroviral options were started on
open-label fostemsavir plus optimized background therapy
61 Consequently, greater drop-in of
open-label glucose-lowering medications occurred in the
62 FORUM is a randomized, controlled,
open-label,
international, multicenter, phase III, nonin
63 FeDeriCa, a randomised,
open-label,
international, multicentre, non-inferiority,
64 We conducted an
open-label,
international, randomized, phase 3 trial inv
65 Of these, 403 were randomized to
open-label interventions within the corticosteroid domai
66 In this
open-label,
investigator-initiated, randomised phase 2 t
67 Four of the 6 patients entering the
open-label IVIG arm reported >=50% reduction in seizure
68 nging background medications or switching to
open-label ixekizumab Q2W, or both, was allowed after we
69 Patients who switched to
open-label ixekizumab were imputed as non-responders in
70 sion that reported results of the phase III,
open-label KATHERINE trial.
71 IC) in 25 patients with TRD during a 1-year,
open-label,
maintenance period, which followed a 1-year
72 ding, participants in the MDMA group had one
open-label MDMA session and placebo participants crossed
73 o participants crossed over to receive three
open-label MDMA sessions.
74 hich patients were treated for 16 weeks with
open-label medication.
75 We performed a randomized, adaptive,
open-label,
multicenter clinical trial.
76 In this
open-label,
multicenter, noninferiority trial, we recrui
77 TANGO is an
open-label,
multicenter, phase 3 study that randomized a
78 GO30140 is an
open-label,
multicentre, multiarm, phase 1b study that e
79 POETIC was an
open-label,
multicentre, parallel-group, randomised, pha
80 GEN501 was an
open-label,
multicentre, phase 1-2, dose escalation and
81 SIRIUS was an
open-label,
multicentre, phase 2 study done in Canada, S
82 This was a randomised,
open-label,
multicentre, phase 3 trial done at ten centr
83 SPRINT was an
open-label,
multicentre, randomised controlled trial und
84 macokinetic and safety substudies within the
open-label,
multicentre, randomised ODYSSEY trial (NCT02
85 This phase 2,
open-label,
multicentre, randomised, controlled trial wa
86 We did an
open-label,
multicentre, randomised, phase 2 trial at si
87 This was an
open-label,
multicentre, single-arm phase 2 trial done a
88 This
open-label,
multicentre, single-arm, phase 2 trial was d
89 We did an
open-label,
multicohort, phase 2a, platform trial of ctD
90 amme (TOP), which began >10 years ago, is an
open-label,
multinational, prospective observational stu
91 ed PD Rating Scale-I (MDS-UPDRS-I) underwent
open-label nabilone titration (0.25 mg once daily to 1 m
92 king paradigms (ADPs) separated by a week of
open-label naltrexone (100 mg daily).
93 The prospective, randomised,
open-label,
non-inferiority NOBLE trial was done at 36 h
94 This randomised,
open-label,
non-inferiority phase 3 trial, was done at t
95 SIMPL'HIV was a multicenter,
open-label,
non-inferiority randomized trial with a fact
96 We conducted a randomized, controlled,
open-label,
non-inferiority trial (10% margin) to compar
97 In this
open-label,
non-inferiority trial, we enrolled people wi
98 nary syndrome (POPular AGE): the randomised,
open-label,
non-inferiority trial.
99 We did an
open-label,
non-inferiority, randomised (1:1 with blocks
100 We did an
open-label,
non-inferiority, randomised controlled trial
101 ng, multicentre (147 sites in 18 countries),
open-label,
non-inferiority, randomised, phase 3 trial,
102 In the multi-cohort,
open-label,
non-randomised, phase 2 KEYNOTE-158 study, p
103 This study was an investigator-initiated,
open-label,
non-randomised, single-arm, single centre, p
104 This is a phase 3, randomized,
open-label,
noninferiority trial conducted in patients w
105 ational, randomized, investigator-initiated,
open-label,
noninferiority trial with blinded central ou
106 In this prospective,
open-label,
observational trial at a harm reduction orga
107 This multi-center, prospective,
open-label,
observational, single-arm trial of 1200 pati
108 Open-label oral celecoxib (200 mg, twice daily) was admi
109 This
open label,
parallel group, randomised controlled trial
110 In this single-center, phase 1,
open-label,
parallel-group study, 8 patients were assign
111 In a 16-week, multicenter, randomized,
open-label,
parallel-group trial, we assigned, in a 3:1
112 DIVERSITY is a randomised, controlled,
open-label,
parallel-group, phase 2b/3 non-inferiority t
113 This was an
open-label,
parallel-group, randomized, controlled trial
114 nd mechanistic parameters following extended
open-label peanut epicutaneous immunotherapy.
115 ll patients received active treatment in the
open-label period for up to 5 years.
116 uring double-blind treatment, but during the
open-label period, more rapid progression was noted amon
117 In this
open-label phase 2 study (ClinicalTrials.gov identifier:
118 This
open-label phase 2 study (CONTRALTO) assessed the safety
119 occurred first; participants could enter an
open-label phase after the occurrence of a protocol-defi
120 Here we report the results of a single-arm
open-label phase I clinical trial designed to determine
121 with BNT162b1 from a second, non-randomized
open-label phase I/II trial in healthy adults, 18-55 yea
122 The
open-label phase is ongoing with no new enrolment, and c
123 dence of MG infection in MSM enrolled in the
open-label phase of the ANRS IPERGAY trial with on deman
124 We did a single-centre,
open-label,
phase 1 dose-escalation and basket dose-expa
125 The multicentre,
open-label,
phase 1-2 AG221-C-001 trial enrolled patient
126 ional, dose-confirmation and dose-expansion,
open-label,
phase 1-2 study in seven centres in the USA
127 iMATRIX was a multicentre,
open-label,
phase 1-2 trial of patients (aged <30 years)
128 We did a non-randomised,
open-label,
phase 1/2 clinical study in paediatric patie
129 In this multicentre,
open-label,
phase 1/2 trial, patients with relapsed or r
130 The MEDIOLA trial is a multicentre,
open-label,
phase 1/2, basket trial of durvalumab and ol
131 In this multi-arm, multicentre,
open-label,
phase 1b study, we enrolled adult patients (
132 CP-MGAH22-05 was a single-arm,
open-label,
phase 1b-2 dose-escalation and cohort expans
133 In this
open-label,
phase 2 basket study, patients were enrolled
134 In this single-arm,
open-label,
phase 2 basket trial, we recruited patients
135 We conducted S1320, a randomized,
open-label,
phase 2 clinical trial (NCT02196181) evaluat
136 This was an
open-label,
phase 2 study of patients from the Yale Canc
137 We performed an
open-label,
phase 2 study of the safety and efficacy of
138 We conducted an
open-label,
phase 2 trial of selumetinib to determine th
139 up and NRG Oncology multicentre, randomised,
open-label,
phase 2 trial, we enrolled eligible adults (
140 This pivotal
open-label,
phase 2, single-arm trial was done across 25
141 SADAL was a multicentre, multinational,
open-label,
phase 2b study done in 59 sites in 19 countr
142 In the ongoing, randomised,
open-label,
phase 3 KEYNOTE-426 study, adults (>=18 year
143 report the 5-year results for a randomised,
open-label,
phase 3 study (RESPONSE) that enrolled patie
144 In this randomised, multicentre,
open-label,
phase 3 study, 466 patients recruited from 1
145 We conducted a multicenter, randomized,
open-label,
phase 3 trial comparing the efficacy and saf
146 CLL14 is a multicentre, randomised,
open-label,
phase 3 trial done at 196 sites in 21 countr
147 We conducted a randomized,
open-label,
phase 3 trial evaluating the PARP inhibitor
148 In an
open-label,
phase 3 trial, we randomly assigned patients
149 The LACC trial was a randomised,
open-label,
phase 3, non-inferiority trial done in 33 ce
150 In this multicentre,
open-label,
phase 3, randomised controlled trial (the EN
151 a, South Korea, Spain, Sweden, and the USA),
open-label,
phase 3b, non-inferiority study of cabotegra
152 CARD was a randomised, multicentre,
open-label,
phase 4 study involving 62 clinical sites ac
153 We conducted a multicenter,
open-label,
phase I, dose escalation and expansion study
154 Here, we report the first
open-label,
phase Ib clinical trial of a personalized ne
155 In an update of the randomized,
open-label,
phase III European Mantle Cell Lymphoma (MCL
156 This was a randomized,
open-label,
phase III trial.
157 Prospective, multicenter,
open-label,
phase IV intervention study in 14 specialist
158 elve healthy volunteers (7F/5M) completed an
open-label pilot study including assessments 1-day befor
159 ere enrolled in a prospective single-center,
open-label pilot study.
160 with sickle cell disease in a single-center,
open-label pilot study.
161 This study investigated the efficacy of an
open-label placebo (OLP) treatment for menopausal hot fl
162 Results indicate that
open-label placebos may be an effective, safe alternativ
163 In this randomized, controlled,
open-label platform trial comparing a range of possible
164 DESIGN, SETTING, AND PARTICIPANTS: Parallel,
open-label,
pragmatic randomized clinical trial conducte
165 We did an
open-label,
pragmatic, adaptive, randomised controlled t
166 For this
open-label,
pragmatic, multicenter, non-inferiority, ran
167 The depressed group then received
open-label pramipexole treatment for 6 weeks (0.5 mg/day
168 d over the prefrontal cortex according to an
open-label protocol.
169 We did an
open-label,
randomised clinical trial at 57 centres in B
170 HiLo was a non-inferiority, parallel,
open-label,
randomised controlled factorial trial done a
171 We did a phase 3,
open-label,
randomised controlled trial at 71 hospitals
172 Investigators did an
open-label,
randomised controlled trial at three HIV tre
173 An
open-label,
randomised controlled trial was done at 19 h
174 In this
open-label,
randomised controlled trial, adults (aged 16
175 In a multicentre, parallel-group,
open-label,
randomised study, children (aged 0-17 years)
176 In this multicentre,
open-label,
randomised trial, we recruited patients with
177 In this
open-label,
randomised, controlled trial done at 120 aca
178 DANUBE is an
open-label,
randomised, controlled, phase 3 trial in pat
179 New EPOC was a multicentre,
open-label,
randomised, controlled, phase 3 trial.
180 In this
open-label,
randomised, controlled, phase 3, three-arm,
181 We did an
open-label,
randomised, non-inferiority, phase 3 trial i
182 PANORAMA 3 is an
open-label,
randomised, phase 2 study being done at 71 s
183 In this multicentre,
open-label,
randomised, phase 2 study, 11 different cent
184 EORTC-62092 is an
open-label,
randomised, phase 3 study done in 31 researc
185 This multicentre,
open-label,
randomised, phase 3 trial, was done in 159 a
186 D PARTICIPANTS: Multicenter, parallel-group,
open-label randomized clinical trial of upper airway sur
187 We performed an
open-label randomized controlled phase III study compari
188 An
open-label randomized controlled trial was conducted in
189 were enrolled into a substudy of UChoose, an
open-label randomized crossover study (NCT02404038), com
190 In a phase 2 multicenter
open-label randomized trial sponsored by the National In
191 A multicenter, phase 3,
open label,
randomized (1:1) trial of patients with bord
192 We conducted a multicenter,
open label,
randomized controlled trial in Catalonia (Sp
193 he international, multicenter, non-inferior,
open label,
randomized, controlled trials COLOR and COLO
194 DESIGN, SETTING, AND PARTICIPANTS:
Open-label,
randomized clinical trial conducted at 17 UK
195 DESIGN, SETTING, AND PARTICIPANTS:
Open-label,
randomized clinical trial conducted at 27 ho
196 e United States into 2 identically designed,
open-label,
randomized clinical trials.
197 In this prospective,
open-label,
randomized controlled pilot trial with a 2 x
198 In an
open-label,
randomized controlled trial (RCT), consecuti
199 We performed a multicenter,
open-label,
randomized controlled trial at 13 study cent
200 nsplant Clinical Trials Network multicenter,
open-label,
randomized phase 2 trial to estimate the dif
201 In this multicenter,
open-label,
randomized phase II investigator-sponsored n
202 ) is an investigator-initiated, multicenter,
open-label,
randomized study.
203 We conducted an
open-label,
randomized trial to test whether a moxifloxa
204 An
open-label,
randomized, 3-arm pharmacokinetic interactio
205 This phase 4, multicenter,
open-label,
randomized, control trial enrolled 360 child
206 We conducted a multicenter, prospective,
open-label,
randomized, controlled trial at six hospital
207 We designed an
open-label,
randomized, multicenter, two-arm phase II tr
208 This was a parallel-group,
open-label RCT conducted at the National Hospital in Gui
209 purposely received ivermectin as part of the
open-label RCT.
210 ysis of data from a multicenter, randomized,
open-label,
registry-based clinical trial.
211 In this phase 3, multicentre,
open-label,
repeat-dose study done in 33 centres (hospit
212 A multicenter,
open-label,
repeated-dose, phase I study was conducted t
213 Open-label retransplantation was offered after the trial
214 79 who had undergone thrombectomy during an
open-label roll-in period.
215 with treatment-resistant depression received
open-label SAINT.
216 es of Health-sponsored phase 3, prospective,
open-label,
single-arm pivotal trial of PHPI, was conduc
217 clinical trials are lacking, we conducted an
open-label,
single-arm study to determine the impact of
218 In this
open-label,
single-arm study, patients with HoFH or seve
219 EAY131-H is an
open-label,
single-arm study.
220 This multicenter,
open-label,
single-arm, 2-stage clinical trial was desig
221 We did a multicentre,
open-label,
single-arm, dose-confirmation and dose-expan
222 In this
open-label,
single-arm, multicenter, international pilot
223 This study is part of an ongoing, phase 2,
open-label,
single-arm, multicentre, Rare Oncology Agnos
224 In this multicentre,
open-label,
single-arm, multicohort, phase 2 study (FIGH
225 ay 2017 and December 2018, this prospective,
open-label,
single-arm, observational clinical trial, co
226 In this multicentre,
open-label,
single-arm, phase 2 study (L-MIND), patients
227 This study was an
open-label,
single-arm, phase 2 trial done at 38 clinics
228 In this
open-label,
single-arm, phase 2 trial, patients with rec
229 An
open-label,
single-arm, Phase 3 study was conducted in J
230 In this
open-label,
single-arm, phase 3 trial, participants were
231 This
open-label,
single-arm, prospective cohort trial is the
232 The study was an
open-label,
single-arm, single-center secukinumab treatm
233 This study was an
open-label,
single-arm, three-cohort phase 2 trial done
234 = 43) or 3 annual doses of IA (n = 52) in an
open-label,
single-blinded trial.
235 eport the results of a phase II, randomized,
open-label,
single-center trial in adults aged 18 to 45
236 In an
open-label,
single-group study in which follow-up is ong
237 ody), administered with dexamethasone, in an
open-label,
single-group, phase 2-3 study involving pati
238 We conducted a randomized,
open-label,
single-site study in 103 previously unvaccin
239 CASPIAN is an ongoing,
open-label,
sponsor-blind, randomised, controlled phase
240 on is mainly based on case reports and small
open label studies and the effects these drugs have on c
241 Ten
open-label studies (n = 3292) reported small improvement
242 major depressive episode were enrolled in an
open-label study and received ezogabine up to 900 mg/day
243 We conducted a randomized, prospective,
open-label study at Novant Health Forsyth Medical Center
244 study is a 3-month, multicenter, randomized,
open-label study designed to evaluate whether a delayed
245 This multicenter,
open-label study enrolled 23 subjects with compensated c
246 took a prospective, multicentre, single-arm,
open-label study in adults aged >40 years with significa
247 noncomparative, active-control, randomized,
open-label study in HIV-1-infected antiretroviral therap
248 LEVATE TN is a global, phase 3, multicentre,
open-label study in patients with treatment-naive chroni
249 This was a 24-week, single-arm,
open-label study in treatment-experienced adults living
250 A5308 was a prospective,
open-label study of rilpivirine/emtricitabine/tenofovir
251 This study was a phase II, multicenter,
open-label study of two dose cohorts of bermekimab in pa
252 An
open-label study suggested that vosoritide administratio
253 a multicenter prospective and retrospective,
open-label study using sofosbuvir-based DAA therapy to t
254 Conclusion: In this
open-label study, NGM282 improved the histological featu
255 In an
open-label study, patients 3 to <6 years old chronically
256 In this
open-label study, we assessed the histological efficacy
257 s single-centre, non-randomised, prospective
open-label study, we evaluated and compared the efficacy
258 In an
open-label study, we evaluated the safety and efficacy o
259 solateral prefrontal cortex in a prospective
open-label study.
260 e tablet, Astellas Pharma) for 4 weeks in an
open-label study.
261 This is a prospective, single-arm,
open-label study.
262 In this phase 3,
open-label,
superiority trial in Uganda, we randomly ass
263 Randomized (1:1),
open-label,
superiority-controlled trial compared WOCA p
264 Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n
265 We conducted a multicenter, randomized,
open-label,
three-group, controlled trial involving hosp
266 In an
open-label titration phase, increasing doses of apomorph
267 of patients had adverse events (AEs) during
open-label titration, most of them were transient.
268 tals in Australia and 1 in New Zealand using
open-label treatment and blinded assessment of radiologi
269 ere in stage 1 and was maintained throughout
open-label treatment.
270 apply 1.5% RUX BID for 4 additional weeks of
open-label treatment.
271 nt allocation was fixed; this was denoted an
open-label trial (OLT).
272 This Phase I
open-label trial assessed the safety, efficacy in preven
273 In this controlled,
open-label trial comparing a range of possible treatment
274 types of influenza vaccines in a randomized,
open-label trial during the 2018-2019 influenza season w
275 This investigator-initiated, randomized,
open-label trial evaluated olanzapine in children (ages
276 We did a randomised,
open-label trial in eight academic hospitals in Canada.
277 ion Over Prasugrel: A Multicenter Randomized
Open-Label Trial in Patients with ST-Elevation Myocardia
278 We conducted a phase 3, randomized,
open-label trial in which adults with HIV-1 infection wh
279 S Clinical Trials Group A5312 is a Phase 2A,
open-label trial in which individuals with smear-positiv
280 We conducted a phase 1, dose-escalation,
open-label trial including 45 healthy adults, 18 to 55 y
281 We conducted a phase 1, dose-escalation,
open-label trial of a messenger RNA vaccine, mRNA-1273,
282 We conducted a multicenter, randomized,
open-label trial to evaluate myomectomy, as compared wit
283 We did a cluster-randomised controlled,
open-label trial using a two-by-two factorial design of
284 This phase 2, three-group,
open-label trial was done across 75 hospitals, clinics,
285 This phase 3, randomised,
open-label trial was done at 123 sites in 21 countries.
286 In a randomized
open-label trial, 24 participants were infected by bites
287 In this randomised,
open-label trial, DolPHIN-2, we recruited pregnant women
288 In this phase 1-2a
open-label trial, we consecutively assigned 16 previousl
289 We did a multicentre, randomised,
open-label trial, with blinded outcome assessment of thr
290 KEYNOTE-051 is an ongoing phase 1-2
open-label trial.
291 There was no masking in this
open-label trial.
292 is was a phase III, multicenter, randomized,
open-label trial.
293 Randomized, controlled, and
open-labeled trials published from 2011 through 2020 wer
294 This was an
open-label,
two-arm, non-inferiority, multi-center, rand
295 DREAMM-2 is an
open-label,
two-arm, phase 2 study done at 58 multiple m
296 This pragmatic, parallel-group, multicentre,
open-label,
two-arm, randomised superiority trial includ
297 We conducted a phase IIa,
open-label,
two-cohort study to assess the safety, effic
298 Patients in the control group could receive
open-label veliparib monotherapy after disease progressi
299 Part 2 was an
open-label volunteer infection study using the Plasmodiu
300 Trials were
open-label,
with minimal heterogeneity of effects across